Morgan Stanley resumed coverage of McKesson with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $630.00 | Neutral | Mizuho |
| 11/7/2024 | $531.00 → $688.00 | Neutral → Outperform | Robert W. Baird |
| 9/24/2024 | $603.00 → $531.00 | Outperform → Neutral | Robert W. Baird |
| 9/5/2024 | $670.00 → $665.00 | Outperform | Leerink Partners |
| 8/8/2024 | $540.00 → $570.00 | Neutral | Mizuho |
| 2/26/2024 | $600.00 | Outperform | Leerink Partners |
| 1/3/2024 | $537.00 | Overweight | Barclays |
| 12/14/2023 | $502.00 | Equal Weight | Wells Fargo |
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
DEFA14A - MCKESSON CORP (0000927653) (Filer)
DEF 14A - MCKESSON CORP (0000927653) (Filer)
8-K - MCKESSON CORP (0000927653) (Filer)
Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00
Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously
Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously
McKesson Corporation (NYSE:MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson's leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company's strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along with the company's slide presentation will be available on McKesson's Investor Relations website at investor.mckesson.com, where you can find a complete listing of upcoming events, including details and updates. About McKesson Corporati
Strengthens Community-Based Oncology Care with Florida Cancer Specialists & Research Institute Core Ventures McKesson Corporation (NYSE:MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling intere
McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)